UK CAB 6: Friday August 2003

On Line Registration

Notes for the meeting

Introduction to meeting and speakers
Reading Material
Background information - GSK
Agenda for the meeting
Venue Details

Report from the meeting

Report from 6th UK CAB meeting

PowerPoint Slides from the meeting [some of these are large files]

Feedback report from IAS meeting by Rosy Weston:

CAB6-IAS_RosyWeston.pdf [1.1MB] (pdf file)
CAB6-IAS_RosyWeston.ppt [4.2MB] (powerpoint file)

Feedback report from Resistance and Lipodystrophy workshops by Simon Collins

CAB6-SimonCollins.pdf [0.5MB] (pdf file)
CAB6-SimonCollins.ppt [1.0MB] (powerpoint file)

Background information - GSK

GlaxoSmithKline (GSK) are one of the largest pharmaceutical companies involved in HIV medications and currently have four licensed HIV drugs:

- abacavir (Ziagen)
- AZT (Retrovir)
- 3TC (lamivudine, Epivir)
- amprenavir (Agenerase) and new formulation FosAmprenavir

They produce two combined versions of some of these drugs:

- Combivir (AZT+3TC)
- Trizivir (AZT+3TC+abacavir)

They are also working on new anti-HIV drugs in their development pipeline.

The history of their involvement in HIV/AIDS started with with development of AZT, the first licensed HIV drug, by the Boroughs Wellcome charitable foundation in the 1980. A merger lead to Glaxo Wellcome and when GW merged with SmithKline Beecham in December 2000 GSK became the world's second largest drug company with turnover in excess of $22 billion.

Dr Claudio Avila is GSKs HIV Medical Advisor and will be able to answer questions on current and pipeline drugs including side effects and any ongoing research.

An agenda for the meeting is included below but there will be plenty of opportunity to ask other questions not included here and we are looking forward to a good discussion.

Provisional Agenda for the meeting

8:45	Registration and coofee/tea
9:15	Introduction and welcome to the 6th UK-CAB
9:30	Training session.1
Reports and discussion of new data from IAS HIV conference in Paris Rosy Weston, HIV Pharmacist, St Marys Hospital Including: triple nucleoside studies T-20 update FTC - a new once daily nuke new formulations of saquinavir and nelfinavir SIMBA study (reducing mother-to-baby transmission and breast-feeding)
11:00	Coffee Break
11:30-1:00	Reports and discussion of new data from: Lipodystrophy Workshop in Paris Resistance Workshop in Mexico Speaker: tbc
1:00-2:00	Lunch
2:00-2:30	Internal meeting
2:30-4:30	Afternoon Session:
GlaxoSmithKline - Dr Claudio Avila, HIV Medical Advisor ACTG 5095 report (Trial with early termination of Trizivir arm) Interaction between abacavir and tenofovir - GSK study and letter to doctors Fosamprenavir - including interactions in dual-PI combinations Ongoing research with current drugs - side effects and toxicity, lipodystrophy etc Neuropathy and 3TC and abacavir Pigment/nail changes with AZT Viral fitness and 184V mutation New pipeline drugs
4:30	Meeting close

Previous Meetings | Member Organisations | Join The CAB